Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma.
The etiologic relationship of the Epstein-Barr virus (EBV) to nasopharyngeal carcinoma prompted this study of the efficacy of interferon-gamma (IFN-gamma), which possesses antiviral and antitumor activity, in the treatment of recurrent carcinoma. Fourteen patients received recombinant IFN-gamma in daily intramuscular doses of 5-10 X 10(6) U/m2. Of 13 patients evaluable for response, five had a minor response; disease was stable in two and had progressed in six. EBV serology for immunoglobin (Ig) G, IgA-VCA, and early antigen was measured in six patients. In four of these, titers rose consistently with disease progression and in one patient, titers decreased with minor response.
Dimery
I W
IW
Department of Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Jacobs
C
C
Tseng
A
A
Saks
S
S
Pearson
G
G
Hong
W K
WK
Gutterman
J U
JU
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D005260:Female; D004854:Herpesvirus 4, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D011994:Recombinant Proteins; D012008:Recurrence
D000914:Antibodies, Viral; D000956:Antigens, Viral; D011994:Recombinant Proteins; D007371:Interferon-gamma